SELLAS Announces FDA Rare Pediatric Disease Designation for Its Leukemia Treatment

Seeking AlphaOct 15 09:34 ET

Sellas Life Sciences Announces U.S. FDA Granted RPDD to GPS

TipRanksOct 15 08:50 ET

Express News | Sellas Life Sciences Group Inc - Gps Phase 3 Regal Trial Interim Analysis Expected in Q4 2024

ReutersOct 15 08:45 ET

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

GlobeNewswireOct 15 08:45 ET

Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia

ReutersOct 15 08:45 ET

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswireOct 10 16:05 ET